Propofol Comprehensive Study by Type (Local Anaesthesia, General Anesthesia), Application (Medical Uses, Other Uses), Route of Administration (Intravenous, Inhalational) Players and Region - Global Market Outlook to 2026

Propofol Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Propofol is a prescription, injectable anaesthetic drug used to decrease the activity of the brain and central nervous system. It is administered intravenously and is widely utilized in general anaesthesia to perform minimally invasive surgeries. Propofol is used in sedation procedures for mechanically ventilated adults, in procedural sedation, and for status epilepticus when other drugs have not produced desired results.This growth is primarily driven by Increasing In Number Of Cataract Removal Surgeries and Rapidly Increase In Number Of Orthodontic And Dental Surgical Procedures.

Globally, a noticeable market trend is evident Research And Development Activities Initiated By The Leading Players For New Products Development. Major Players, such as Astrazeneca plc (United Kingdom), Baxter International Inc. (United States), Hikma Pharmaceuticals PLC (United Kingdom), Mylan N.V. (United States), B.Braun Melsungen (Germany), Eisai Co., Ltd. (Japan), Bachem (Switzerland), Fresenius Se & Co. Kgaa (Germany), Hospira, Inc. (United Kingdom) and Par Pharmaceutical Companies, Inc. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In Jan 2019, Dr. Reddy's Laboratories announces the launch of Propofol Injectable Emulsion, USP in the U.S. Market.

Regulatory Insights:
"FDA has issued alert to inform healthcare professionals about several clusters of patients who have experienced chills, fever, and body aches shortly after receiving propofol for sedation or general anesthesia. FDA has tested multiple units of propofol vials and lots used in patients who have experienced these symptoms and to date, these tests have not identified any vials contaminated with bacteria or endotoxins."

Market Drivers
  • Increasing In Number Of Cataract Removal Surgeries
  • Rapidly Increase In Number Of Orthodontic And Dental Surgical Procedures

Market Trend
  • Research And Development Activities Initiated By The Leading Players For New Products Development

Restraints
  • High Cost involved in Propofol

Opportunities
Increase In The Number Of General Surgical Procedures
Challenges
Side Effects Such As Reduced Heart Rate And Low Blood Pressure

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Propofol Study Sheds Light on
— The Propofol Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Propofol industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Propofol industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Local Anaesthesia
  • General Anesthesia
By Application
  • Medical Uses
  • Other Uses
By Route of Administration
  • Intravenous
  • Inhalational

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing In Number Of Cataract Removal Surgeries
      • 3.2.2. Rapidly Increase In Number Of Orthodontic And Dental Surgical Procedures
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Such As Reduced Heart Rate And Low Blood Pressure
    • 3.4. Market Trends
      • 3.4.1. Research And Development Activities Initiated By The Leading Players For New Products Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Propofol, by Type, Application, Route of Administration and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Propofol (Value)
      • 5.2.1. Global Propofol by: Type (Value)
        • 5.2.1.1. Local Anaesthesia
        • 5.2.1.2. General Anesthesia
      • 5.2.2. Global Propofol by: Application (Value)
        • 5.2.2.1. Medical Uses
        • 5.2.2.2. Other Uses
      • 5.2.3. Global Propofol by: Route of Administration (Value)
        • 5.2.3.1. Intravenous
        • 5.2.3.2. Inhalational
      • 5.2.4. Global Propofol Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Propofol (Price)
      • 5.3.1. Global Propofol by: Type (Price)
  • 6. Propofol: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astrazeneca plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Baxter International Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan N.V. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. B.Braun Melsungen (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eisai Co., Ltd. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bachem (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Fresenius Se & Co. Kgaa (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hospira, Inc. (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Par Pharmaceutical Companies, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Propofol Sale, by Type, Application, Route of Administration and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Propofol (Value)
      • 7.2.1. Global Propofol by: Type (Value)
        • 7.2.1.1. Local Anaesthesia
        • 7.2.1.2. General Anesthesia
      • 7.2.2. Global Propofol by: Application (Value)
        • 7.2.2.1. Medical Uses
        • 7.2.2.2. Other Uses
      • 7.2.3. Global Propofol by: Route of Administration (Value)
        • 7.2.3.1. Intravenous
        • 7.2.3.2. Inhalational
      • 7.2.4. Global Propofol Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Propofol (Price)
      • 7.3.1. Global Propofol by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Propofol: by Type(USD Million)
  • Table 2. Propofol Local Anaesthesia , by Region USD Million (2015-2020)
  • Table 3. Propofol General Anesthesia , by Region USD Million (2015-2020)
  • Table 4. Propofol: by Application(USD Million)
  • Table 5. Propofol Medical Uses , by Region USD Million (2015-2020)
  • Table 6. Propofol Other Uses , by Region USD Million (2015-2020)
  • Table 7. Propofol: by Route of Administration(USD Million)
  • Table 8. Propofol Intravenous , by Region USD Million (2015-2020)
  • Table 9. Propofol Inhalational , by Region USD Million (2015-2020)
  • Table 10. South America Propofol, by Country USD Million (2015-2020)
  • Table 11. South America Propofol, by Type USD Million (2015-2020)
  • Table 12. South America Propofol, by Application USD Million (2015-2020)
  • Table 13. South America Propofol, by Route of Administration USD Million (2015-2020)
  • Table 14. Brazil Propofol, by Type USD Million (2015-2020)
  • Table 15. Brazil Propofol, by Application USD Million (2015-2020)
  • Table 16. Brazil Propofol, by Route of Administration USD Million (2015-2020)
  • Table 17. Argentina Propofol, by Type USD Million (2015-2020)
  • Table 18. Argentina Propofol, by Application USD Million (2015-2020)
  • Table 19. Argentina Propofol, by Route of Administration USD Million (2015-2020)
  • Table 20. Rest of South America Propofol, by Type USD Million (2015-2020)
  • Table 21. Rest of South America Propofol, by Application USD Million (2015-2020)
  • Table 22. Rest of South America Propofol, by Route of Administration USD Million (2015-2020)
  • Table 23. Asia Pacific Propofol, by Country USD Million (2015-2020)
  • Table 24. Asia Pacific Propofol, by Type USD Million (2015-2020)
  • Table 25. Asia Pacific Propofol, by Application USD Million (2015-2020)
  • Table 26. Asia Pacific Propofol, by Route of Administration USD Million (2015-2020)
  • Table 27. China Propofol, by Type USD Million (2015-2020)
  • Table 28. China Propofol, by Application USD Million (2015-2020)
  • Table 29. China Propofol, by Route of Administration USD Million (2015-2020)
  • Table 30. Japan Propofol, by Type USD Million (2015-2020)
  • Table 31. Japan Propofol, by Application USD Million (2015-2020)
  • Table 32. Japan Propofol, by Route of Administration USD Million (2015-2020)
  • Table 33. India Propofol, by Type USD Million (2015-2020)
  • Table 34. India Propofol, by Application USD Million (2015-2020)
  • Table 35. India Propofol, by Route of Administration USD Million (2015-2020)
  • Table 36. South Korea Propofol, by Type USD Million (2015-2020)
  • Table 37. South Korea Propofol, by Application USD Million (2015-2020)
  • Table 38. South Korea Propofol, by Route of Administration USD Million (2015-2020)
  • Table 39. Taiwan Propofol, by Type USD Million (2015-2020)
  • Table 40. Taiwan Propofol, by Application USD Million (2015-2020)
  • Table 41. Taiwan Propofol, by Route of Administration USD Million (2015-2020)
  • Table 42. Australia Propofol, by Type USD Million (2015-2020)
  • Table 43. Australia Propofol, by Application USD Million (2015-2020)
  • Table 44. Australia Propofol, by Route of Administration USD Million (2015-2020)
  • Table 45. Rest of Asia-Pacific Propofol, by Type USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Propofol, by Application USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Propofol, by Route of Administration USD Million (2015-2020)
  • Table 48. Europe Propofol, by Country USD Million (2015-2020)
  • Table 49. Europe Propofol, by Type USD Million (2015-2020)
  • Table 50. Europe Propofol, by Application USD Million (2015-2020)
  • Table 51. Europe Propofol, by Route of Administration USD Million (2015-2020)
  • Table 52. Germany Propofol, by Type USD Million (2015-2020)
  • Table 53. Germany Propofol, by Application USD Million (2015-2020)
  • Table 54. Germany Propofol, by Route of Administration USD Million (2015-2020)
  • Table 55. France Propofol, by Type USD Million (2015-2020)
  • Table 56. France Propofol, by Application USD Million (2015-2020)
  • Table 57. France Propofol, by Route of Administration USD Million (2015-2020)
  • Table 58. Italy Propofol, by Type USD Million (2015-2020)
  • Table 59. Italy Propofol, by Application USD Million (2015-2020)
  • Table 60. Italy Propofol, by Route of Administration USD Million (2015-2020)
  • Table 61. United Kingdom Propofol, by Type USD Million (2015-2020)
  • Table 62. United Kingdom Propofol, by Application USD Million (2015-2020)
  • Table 63. United Kingdom Propofol, by Route of Administration USD Million (2015-2020)
  • Table 64. Netherlands Propofol, by Type USD Million (2015-2020)
  • Table 65. Netherlands Propofol, by Application USD Million (2015-2020)
  • Table 66. Netherlands Propofol, by Route of Administration USD Million (2015-2020)
  • Table 67. Rest of Europe Propofol, by Type USD Million (2015-2020)
  • Table 68. Rest of Europe Propofol, by Application USD Million (2015-2020)
  • Table 69. Rest of Europe Propofol, by Route of Administration USD Million (2015-2020)
  • Table 70. MEA Propofol, by Country USD Million (2015-2020)
  • Table 71. MEA Propofol, by Type USD Million (2015-2020)
  • Table 72. MEA Propofol, by Application USD Million (2015-2020)
  • Table 73. MEA Propofol, by Route of Administration USD Million (2015-2020)
  • Table 74. Middle East Propofol, by Type USD Million (2015-2020)
  • Table 75. Middle East Propofol, by Application USD Million (2015-2020)
  • Table 76. Middle East Propofol, by Route of Administration USD Million (2015-2020)
  • Table 77. Africa Propofol, by Type USD Million (2015-2020)
  • Table 78. Africa Propofol, by Application USD Million (2015-2020)
  • Table 79. Africa Propofol, by Route of Administration USD Million (2015-2020)
  • Table 80. North America Propofol, by Country USD Million (2015-2020)
  • Table 81. North America Propofol, by Type USD Million (2015-2020)
  • Table 82. North America Propofol, by Application USD Million (2015-2020)
  • Table 83. North America Propofol, by Route of Administration USD Million (2015-2020)
  • Table 84. United States Propofol, by Type USD Million (2015-2020)
  • Table 85. United States Propofol, by Application USD Million (2015-2020)
  • Table 86. United States Propofol, by Route of Administration USD Million (2015-2020)
  • Table 87. Canada Propofol, by Type USD Million (2015-2020)
  • Table 88. Canada Propofol, by Application USD Million (2015-2020)
  • Table 89. Canada Propofol, by Route of Administration USD Million (2015-2020)
  • Table 90. Mexico Propofol, by Type USD Million (2015-2020)
  • Table 91. Mexico Propofol, by Application USD Million (2015-2020)
  • Table 92. Mexico Propofol, by Route of Administration USD Million (2015-2020)
  • Table 93. Propofol: by Type(USD/Units)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Propofol: by Type(USD Million)
  • Table 105. Propofol Local Anaesthesia , by Region USD Million (2021-2026)
  • Table 106. Propofol General Anesthesia , by Region USD Million (2021-2026)
  • Table 107. Propofol: by Application(USD Million)
  • Table 108. Propofol Medical Uses , by Region USD Million (2021-2026)
  • Table 109. Propofol Other Uses , by Region USD Million (2021-2026)
  • Table 110. Propofol: by Route of Administration(USD Million)
  • Table 111. Propofol Intravenous , by Region USD Million (2021-2026)
  • Table 112. Propofol Inhalational , by Region USD Million (2021-2026)
  • Table 113. South America Propofol, by Country USD Million (2021-2026)
  • Table 114. South America Propofol, by Type USD Million (2021-2026)
  • Table 115. South America Propofol, by Application USD Million (2021-2026)
  • Table 116. South America Propofol, by Route of Administration USD Million (2021-2026)
  • Table 117. Brazil Propofol, by Type USD Million (2021-2026)
  • Table 118. Brazil Propofol, by Application USD Million (2021-2026)
  • Table 119. Brazil Propofol, by Route of Administration USD Million (2021-2026)
  • Table 120. Argentina Propofol, by Type USD Million (2021-2026)
  • Table 121. Argentina Propofol, by Application USD Million (2021-2026)
  • Table 122. Argentina Propofol, by Route of Administration USD Million (2021-2026)
  • Table 123. Rest of South America Propofol, by Type USD Million (2021-2026)
  • Table 124. Rest of South America Propofol, by Application USD Million (2021-2026)
  • Table 125. Rest of South America Propofol, by Route of Administration USD Million (2021-2026)
  • Table 126. Asia Pacific Propofol, by Country USD Million (2021-2026)
  • Table 127. Asia Pacific Propofol, by Type USD Million (2021-2026)
  • Table 128. Asia Pacific Propofol, by Application USD Million (2021-2026)
  • Table 129. Asia Pacific Propofol, by Route of Administration USD Million (2021-2026)
  • Table 130. China Propofol, by Type USD Million (2021-2026)
  • Table 131. China Propofol, by Application USD Million (2021-2026)
  • Table 132. China Propofol, by Route of Administration USD Million (2021-2026)
  • Table 133. Japan Propofol, by Type USD Million (2021-2026)
  • Table 134. Japan Propofol, by Application USD Million (2021-2026)
  • Table 135. Japan Propofol, by Route of Administration USD Million (2021-2026)
  • Table 136. India Propofol, by Type USD Million (2021-2026)
  • Table 137. India Propofol, by Application USD Million (2021-2026)
  • Table 138. India Propofol, by Route of Administration USD Million (2021-2026)
  • Table 139. South Korea Propofol, by Type USD Million (2021-2026)
  • Table 140. South Korea Propofol, by Application USD Million (2021-2026)
  • Table 141. South Korea Propofol, by Route of Administration USD Million (2021-2026)
  • Table 142. Taiwan Propofol, by Type USD Million (2021-2026)
  • Table 143. Taiwan Propofol, by Application USD Million (2021-2026)
  • Table 144. Taiwan Propofol, by Route of Administration USD Million (2021-2026)
  • Table 145. Australia Propofol, by Type USD Million (2021-2026)
  • Table 146. Australia Propofol, by Application USD Million (2021-2026)
  • Table 147. Australia Propofol, by Route of Administration USD Million (2021-2026)
  • Table 148. Rest of Asia-Pacific Propofol, by Type USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Propofol, by Application USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Propofol, by Route of Administration USD Million (2021-2026)
  • Table 151. Europe Propofol, by Country USD Million (2021-2026)
  • Table 152. Europe Propofol, by Type USD Million (2021-2026)
  • Table 153. Europe Propofol, by Application USD Million (2021-2026)
  • Table 154. Europe Propofol, by Route of Administration USD Million (2021-2026)
  • Table 155. Germany Propofol, by Type USD Million (2021-2026)
  • Table 156. Germany Propofol, by Application USD Million (2021-2026)
  • Table 157. Germany Propofol, by Route of Administration USD Million (2021-2026)
  • Table 158. France Propofol, by Type USD Million (2021-2026)
  • Table 159. France Propofol, by Application USD Million (2021-2026)
  • Table 160. France Propofol, by Route of Administration USD Million (2021-2026)
  • Table 161. Italy Propofol, by Type USD Million (2021-2026)
  • Table 162. Italy Propofol, by Application USD Million (2021-2026)
  • Table 163. Italy Propofol, by Route of Administration USD Million (2021-2026)
  • Table 164. United Kingdom Propofol, by Type USD Million (2021-2026)
  • Table 165. United Kingdom Propofol, by Application USD Million (2021-2026)
  • Table 166. United Kingdom Propofol, by Route of Administration USD Million (2021-2026)
  • Table 167. Netherlands Propofol, by Type USD Million (2021-2026)
  • Table 168. Netherlands Propofol, by Application USD Million (2021-2026)
  • Table 169. Netherlands Propofol, by Route of Administration USD Million (2021-2026)
  • Table 170. Rest of Europe Propofol, by Type USD Million (2021-2026)
  • Table 171. Rest of Europe Propofol, by Application USD Million (2021-2026)
  • Table 172. Rest of Europe Propofol, by Route of Administration USD Million (2021-2026)
  • Table 173. MEA Propofol, by Country USD Million (2021-2026)
  • Table 174. MEA Propofol, by Type USD Million (2021-2026)
  • Table 175. MEA Propofol, by Application USD Million (2021-2026)
  • Table 176. MEA Propofol, by Route of Administration USD Million (2021-2026)
  • Table 177. Middle East Propofol, by Type USD Million (2021-2026)
  • Table 178. Middle East Propofol, by Application USD Million (2021-2026)
  • Table 179. Middle East Propofol, by Route of Administration USD Million (2021-2026)
  • Table 180. Africa Propofol, by Type USD Million (2021-2026)
  • Table 181. Africa Propofol, by Application USD Million (2021-2026)
  • Table 182. Africa Propofol, by Route of Administration USD Million (2021-2026)
  • Table 183. North America Propofol, by Country USD Million (2021-2026)
  • Table 184. North America Propofol, by Type USD Million (2021-2026)
  • Table 185. North America Propofol, by Application USD Million (2021-2026)
  • Table 186. North America Propofol, by Route of Administration USD Million (2021-2026)
  • Table 187. United States Propofol, by Type USD Million (2021-2026)
  • Table 188. United States Propofol, by Application USD Million (2021-2026)
  • Table 189. United States Propofol, by Route of Administration USD Million (2021-2026)
  • Table 190. Canada Propofol, by Type USD Million (2021-2026)
  • Table 191. Canada Propofol, by Application USD Million (2021-2026)
  • Table 192. Canada Propofol, by Route of Administration USD Million (2021-2026)
  • Table 193. Mexico Propofol, by Type USD Million (2021-2026)
  • Table 194. Mexico Propofol, by Application USD Million (2021-2026)
  • Table 195. Mexico Propofol, by Route of Administration USD Million (2021-2026)
  • Table 196. Propofol: by Type(USD/Units)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Propofol: by Type USD Million (2015-2020)
  • Figure 5. Global Propofol: by Application USD Million (2015-2020)
  • Figure 6. Global Propofol: by Route of Administration USD Million (2015-2020)
  • Figure 7. South America Propofol Share (%), by Country
  • Figure 8. Asia Pacific Propofol Share (%), by Country
  • Figure 9. Europe Propofol Share (%), by Country
  • Figure 10. MEA Propofol Share (%), by Country
  • Figure 11. North America Propofol Share (%), by Country
  • Figure 12. Global Propofol: by Type USD/Units (2015-2020)
  • Figure 13. Global Propofol share by Players 2020 (%)
  • Figure 14. Global Propofol share by Players (Top 3) 2020(%)
  • Figure 15. Global Propofol share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Astrazeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Astrazeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Baxter International Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 25. B.Braun Melsungen (Germany) Revenue, Net Income and Gross profit
  • Figure 26. B.Braun Melsungen (Germany) Revenue: by Geography 2020
  • Figure 27. Eisai Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Eisai Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 29. Bachem (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Bachem (Switzerland) Revenue: by Geography 2020
  • Figure 31. Fresenius Se & Co. Kgaa (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Fresenius Se & Co. Kgaa (Germany) Revenue: by Geography 2020
  • Figure 33. Hospira, Inc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Hospira, Inc. (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Par Pharmaceutical Companies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Par Pharmaceutical Companies, Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Global Propofol: by Type USD Million (2021-2026)
  • Figure 38. Global Propofol: by Application USD Million (2021-2026)
  • Figure 39. Global Propofol: by Route of Administration USD Million (2021-2026)
  • Figure 40. South America Propofol Share (%), by Country
  • Figure 41. Asia Pacific Propofol Share (%), by Country
  • Figure 42. Europe Propofol Share (%), by Country
  • Figure 43. MEA Propofol Share (%), by Country
  • Figure 44. North America Propofol Share (%), by Country
  • Figure 45. Global Propofol: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Astrazeneca plc (United Kingdom)
  • Baxter International Inc. (United States)
  • Hikma Pharmaceuticals PLC (United Kingdom)
  • Mylan N.V. (United States)
  • B.Braun Melsungen (Germany)
  • Eisai Co., Ltd. (Japan)
  • Bachem (Switzerland)
  • Fresenius Se & Co. Kgaa (Germany)
  • Hospira, Inc. (United Kingdom)
  • Par Pharmaceutical Companies, Inc. (United States)
Additional players considered in the study are as follows:
Fresenius Kabi (Germany) , Xi'an Libang (China) , Sichuan Guorui (China) , Guangdong Jiabo (China) , Jiangsu Nhwa (China) , Piramal Critical Care Limited (United Kingdom)
Select User Access Type

Key Highlights of Report


Jun 2021 238 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Propofol Market are Astrazeneca plc (United Kingdom), Baxter International Inc. (United States), Hikma Pharmaceuticals PLC (United Kingdom), Mylan N.V. (United States), B.Braun Melsungen (Germany), Eisai Co., Ltd. (Japan), Bachem (Switzerland), Fresenius Se & Co. Kgaa (Germany), Hospira, Inc. (United Kingdom) and Par Pharmaceutical Companies, Inc. (United States) etc.
Propofol is a prescription, injectable anaesthetic drug used to decrease the activity of the brain and central nervous system. It is administered intravenously and is widely utilized in general anaesthesia to perform minimally invasive surgeries. Propofol is used in sedation procedures for mechanically ventilated adults, in procedural sedation, and for status epilepticus when other drugs have not produced desired results.

Know More About Global Propofol Market Report?